World first Drug to ‘dissolve’ Tau-tangles in Alzheimer’s has Phase III Results

28/07/2016 - 3 minutes

The much-anticipated results of TauRx‘s Phase III trial for Alzheimer’s disease have finally been disclosed. Despite some complicated effects, this could be the first available working therapy for Alzheimer’s patients.

taurx tau tangles neurodegeneration alzheimersAccording to the WHO, Alzheimer’s disease is the cause of up to 70% of dementia cases, which translates to over 30 million patients worldwide. As the world population ages, Alzheimer’s is therefore quickly becoming a major global health concern.

Based in Aberdeen (Scotland), TauRx has one of the most advanced and promising candidates for Alzheimer’s among recent breakthroughs in the field.

This candidate is LMTX, which reduces the levels of aggregated misfolded tau proteins – considered a key drivers of Alzheimer’s disease and neurodegeneration.

After showing an 81% reduction in disease progression in LMTX’s Phase II trials, TauRx raised a whopping €120M for the Phase III trials.

Now, the first results from Phase III have been announced.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!